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Abstract 
Background: Small cell lung cancers (SCLC) are tumors of neuroendocrine origin. Previous in vitro studies from our 
laboratory showed that SCLC expresses high levels of the transmembrane dense core vesicle protein IA-2 (islet cell 
antigen-2) as compared to normal lung cells. IA-2, through its effect on dense core vesicles (DCVs), is known to be 
involved in the secretion of hormones and neurotransmitters. It is believed that the dysregulated release of the neu-
rotransmitter Acetylcholine (ACh) by DCVs has an autocrine effect on SCLC cell growth. Recently, we found that IA-2 is 
a target of the microRNA miR-342 and that miR-342 mimics suppress the expression of IA-2. The present experiments 
were initiated to see whether IA-2 and/or miR-342 affect the growth of SCLC.
Methods: SCLC cell growth was evaluated following the knockdown of endogenous IA-2 with RNAi or by overex-
pressing miR-342 with a mimic. The secretion and content of ACh in SCLC cells was analyzed using a human acetyl-
choline ELISA (enzyme-linked immunosorbent assay) kit.
Results: The knockdown of endogenous IA-2 by RNAi reduced SCLC cell growth within 4 days by 40 % or more. 
Similar results were obtained when these cell lines were transfected with a miR-342 mimic. The knockdown of IA-2 
by RNAi or miR-342 with a mimic also resulted in a significant decrease in the secretion of ACh, one of the autocrine 
hormones secreted by SCLC. Further studies revealed that the growth of SCLC cell lines that had been treated with 
the miR-342 mimic was restored to nearly normal levels by treatment with ACh.
Conclusion: Our studies show for the first time that both miR-342 and its target gene IA-2 are involved in the growth 
process of SCLC cells and act by their effect on autocrine secretion. These findings point to possible new therapeutic 
approaches for the treatment of autocrine-induced tumor proliferation.
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Background
Lung cancer is divided into two histopathological types: 
non-small cell lung cancer (NSCLC) accounting for ∼80 
to 85 % of lung cancers, and small cell lung cancer (SCLC) 
which accounts for ∼15 to 20  % of lung cancers [1–4]. 
SCLC has distinctive neuroendocrine features [5] and is 
capable of secreting or co-secreting a variety of neuro-
peptides and neurotransmitters including acetylcholine 
(ACh) [6, 7], pro-opiomelanocortin (POMC), and adren-
ocorticotropic hormone (ACTH) [8, 9]. Of the various 
neuropeptides, ACh, which is an autocrine growth factor, 
facilitates SCLC growth [6, 7].
IA-2 (also known as islet cell antigen 512 [ICA512] or 
protein tyrosine phosphatase, receptor type N [PTPRN]) 
is an integral transmembrane protein of dense core vesi-
cles (DCV) [10, 11], and plays an important role in the 
secretion of hormones and neurotransmitters such as 
insulin, luteinizing hormone (LH), follicular stimulating 
hormone (FSH), norepinephrine (NE), dopamine, and 
renin [10, 12–17]. In addition, IA-2 is highly expressed 
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SCLC tumors, as observed by northern blot analysis 
[18, 19]. IA-2, together with its paralog protein IA-2β 
(also known as phosphatase homologue in granules of 
insulinoma [Phogrin] or protein tyrosine phosphatase, 
receptor type N2 [PTPRN2]), has been implicated in the 
growth of pancreatic β cells [20, 21]. Collectively, these 
studies suggest that IA-2 may be associated with the 
pathogenesis of SCLC, specifically in respect to the regu-
lation of the neuroendocrine secretion.
The role of microRNAs (miRNAs) in tumor growth is 
being widely studied [22]. It is believed that the dysregu-
lation of some miRNAs is linked to lung cancer, and that 
quantification of miRNA expression can be used to study 
disease prognosis. In this context, a recent microarray 
analysis showed that miR-342 is one of the most down-
regulated miRNAs associated with lung cancer [23]. The 
underlying role of miR-342 in the pathogenesis of lung 
cancer, however, remains unclear.
In the present study, we measured the levels of IA-2 
and miR-342 in two SCLC cell lines, and then inhibited 
IA-2 by siRNA transfection and altered miR-342 levels 
with mimics and inhibitors to determine their effect on 
SCLC growth and ACh levels.
Methods
Reagents and cell lines
Predesigned siRNAs (Hs_PTPRN_3, 4, 5, 6) against human 
IA-2 (NM_001199763, NM_001199764, NM_002846), 
scrambled negative control, miR-342 mimic, miR-342 
inhibitor, and HiPerFect Transfection Reagent were 
obtained from Qiagen. For RNA analysis: miRNeasy 
Mini kit, miScript II RT kit, and miScript SYBR Green 
PCR kit also were purchased from Qiagen. SYBR Green 
PCR Master Mix was obtained from Applied Biosystems. 
The human Acetylcholine (ACh) ELISA Kit was used for 
determination of endogenous ACh levels (MyBioSource, 
San Diego, CA). The Cell Counting Kit-8, neostigmine, 
and Acetylcholine chloride were purchased from Sigma-
Aldrich, and the M-PER Mammalian Protein Extraction 
Reagent was obtained from Thermo Fisher Scientific.
Antibodies for western blotting and immunostain-
ing were purchased from Invitrogen. VECTASHIELD 
Mounting Medium with DAPI (4′,6-Diamidino-2-Phe-
nylindole, Dihydrochloride) was obtained from Vector 
Laboratories. Rabbit polyclonal antibody against amino 
acid residues 65–80 of the N-terminal region of IA-2 
(GenBank Acc. No., NP_001186692), was used for both 
Western blotting (1:500) and immunostaining (1:100). 
Both items were purchased from Abgent, San Diego, CA, 
USA [24].
SCLC cell lines (NCI-H82 and NCI-H345) were pur-
chased from ATCC. The NCI-H82 cell line was cul-
tured in Dulbecco’s Modified Eagle Medium (DMEM) 
supplemented with 10  % fetal bovine serum (FBS). The 
NCI-H345 cell line was cultured in DMEM/Ham’s F-12 
(1:1), supplemented with 10  % FBS, insulin (0.005  mg/
ml), transferrin (0.01  mg/ml), sodium selenite (30  nM), 
hydrocortisone (10 nM), beta-estradiol (10 nM), HEPES 
(10 mM), and l-glutamine (2 mM). Both cell lines were 
cultured at 37 °C in 5 % CO2.
Immunofluorescence
Transfected NCI-H82 cells (on chamber slides) were 
fixed in 4  % paraformaldehyde. Primary and secondary 
antibodies (IA-2; 1:100 dilution), and Alexa Fluor 568 
Goat Anti-Rabbit IgG (H+L) (1:500 dilution), respec-
tively, were used. VECTASHIELD mounting medium 
with DAPI (Vector Laboratories) was used for nuclear 
staining. Images were captured with ZEN Imaging Soft-
ware (ZEISS) using constant exposure parameters for 
each fluorescence channel. Images shown are representa-
tive field of three independent experiments.
IA‑2 siRNA transfection
A total of 2 × 104 cells/well were seeded in 24-well cul-
ture plates  1  day prior to undergoing transfection with 
either the IA-2 siRNAs (Hs_PTPRN_3, 4, 5, 6), or the 
scramble siRNA with the HiPerFect Transfection Rea-
gent for 10  min (according the manufacturer’s instruc-
tion). Briefly, cells were resuspended in 100  µl of fresh 
culture medium (containing serum and antibiotics), and 
then 100 μl of the siRNA transfection complexes solution 
(100 nM at final concentration after adding 400 µl culture 
medium) was added drop-wise onto the cells. The plates 
were then gently swirled to ensure uniform distribu-
tion of the transfection complexes. The suspension was 
incubated at normal growth conditions for 6 h, and then 
400 µl of the culture medium (containing serum and anti-
biotics) was added to the cells and incubated until further 
analysis.
MicroRNA mimic and inhibitor transfection
Cells were transfected with the miR-342 mimic or inhibi-
tor, or with the scramble negative control using the 
HiPerFect Transfection Reagent (according to the manu-
facturer’s instructions), and incubated for 10 min further 
analysis. First, cells (2 × 104 cells/well) were transferred 
into 24-well plates after overnight culture. The miRNA 
mimic, miRNA inhibitor, or the control was diluted in 
100  μl culture medium without serum (a final miRNA 
mimic concentration of 5 nM, or a final miRNA inhibi-
tor concentration of 50 nM). Subsequently, the HiPerFect 
Transfection Reagent (3  μl) was added into the diluted 
miRNA mimic/inhibitor solution, and then vortexed. 
After 8  min, the solution was incubated for 10  min at 
room temperature, and then the complexes were added 
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onto the cells. Finally, the cells were incubated with the 
transfection complexes under their normal growth con-
ditions until further analysis.
Cell growth assay
Cell proliferation was tested using the Cell Counting 
Kit-8 (CCK-8) assay according to the manufacturer’s 
instructions (Sigma-Aldrich, St. Louis, MO). In brief, 
after the cells were subjected to the different treat-
ments (transfection with IA-2 siRNA or miR-342 mimic 
or inhibitor), they were cultured for up to 4  days. Cells 
were collected each day and then transferred into 96-well 
plates. Subsequently, CCK-8 (10  µl) was added to each 
well, and then the cells were cultured for another 3 h. Cell 
density was determined by measuring the absorbance at 
450 nm using a VersaMax Microplate Reader (Molecular 
Devices, USA).
ACh secretion and cell content assay
After transfecting the NCI-H82 and NCI-H345 cells with 
either the IA-2 siRNA, miR-342 mimic, or the miR-342 
inhibitor, the cells were incubated for 4  days, and then 
the cells and supernatants were collected [6, 7]. ACh 
level was measured using a human acetylcholine ELISA 
kit according to manufacturer’s protocol. For determina-
tion of ACh release, cell suspensions were collected with 
5 × 10−5 M neostigmine. For measurement of ACh con-
tents, cells were washed in 1× PBS, counted, and then 
sonicated in ice-cold phosphate buffer (pH 7.4) contain-
ing 10−2 M of the acetylcholinesterase inhibitor neostig-
mine. All samples were centrifuged at 1000 rpm for 2 min 
at 4 °C; supernatants were then immediately assayed for 
determination of ACh levels.
Total RNA, miRNA, and quantitative PCR
Total RNA and miRNA were extracted using the miRNe-
asy Mini kit following the manufacturer’s protocol. 
Quantitative RT-PCR for both mRNA and miRNA 
was performed using the miScript II RT kit, and then 
the miScript SYBR Green PCR kit for measuring miR-
342 expression, or SYBR Green PCR Master Mix for 
measuring the expression of IA-2 and GAPDH (glyc-
eraldehyde-3-phosphate dehydrogenase) mRNA with 
a 7500 Real-Time PCR system (Applied Biosystems). 
IA-2 primer sequences used in PCR analysis, for-
ward: 5′-ACGCTCACGCAGTTCCACTT-3′, reverse: 
5′-GCGATGTCAATCTCCTTCAC-3′; GAPDH primer 
sequences, forward: 5′-GAGAACGGGAAGCTTGT 
CAT-3′ reverse: 5′-CAGAGATGATGACCCTTTTGG-3′.
Protein extraction and western blot analysis
Proteins from cells were isolated by M-PER Mamma-
lian Protein Extraction Reagent. Protein concentrations 
were quantified; samples were mixed with reducing load-
ing buffer, and then heated at 70  °C for 10  min. Equal 
amounts of protein was loaded into each lane, and sep-
arated by electrophoresis. Proteins were subsequently 
transferred onto a PVDF (polyvinylidene fluoride) mem-
brane and then blocked in blocking buffer (PBS/0.1  % 
Tween20 (PBS-T)/5  % nonfat-milk). After blocking for 
2 h, blots were incubated over night at 4 °C with the anti-
IA-2  N-terminal antibody (#49) or α-tubulin (1:5000 
dilution). After washing, the blots were incubated for 
30 min at room temperature with HRP (horseradish per-
oxidase) conjugated secondary antibodies. The blots were 
then washed and films were subsequently developed. 
Blots were quantitated using the NIH Image J Software.
ACh rescues NCI‑H82 cell growth
Different concentrations of ACh (0, 1, 10, 100, 300, 1, 
3, and 10  mM) were added to the NCI-H82 cells, and 
4 days later, a cell growth assay was performed. The opti-
mal concentration of ACh was selected, and then added 
to the NCI-H82 cells treated with scramble siRNA, IA-2 
siRNA, miR-342 mimic, or the miR-342 inhibitor. Four 
days later, a cell growth assay was performed to evaluate 
the rescue effect of each treatment condition.
Statistical analysis
All experiments were performed in triplicate and the data 
represent the mean ± SEM. The Student’s t test and One-
way ANOVA were used to determine statistical signifi-
cance. In all cases, a P < 0.05 was considered significant.
Results
Downregulation of IA‑2 by siRNA suppresses SCLC cells 
growth as well as ACh cell content and secretion
NCI-H82 cells were treated with IA-2 siRNA (Hs_
PTPRN_3, 4, 5, 6) and then IA-2 mRNA and IA-2 pro-
tein levels were measured by quantitative real-time PCR 
(qRT-PCR) and Western Blot. Both IA-2 mRNA and 
protein were substantially decreased (Fig.  1a–c). Immu-
nostaining with the IA-2 antibody confirmed the reduc-
tion of IA-2 expression after transfecting the cells with 
the IA-2 siRNA (Fig. 1d).
To elucidate the role of IA-2 on SCLC growth, we 
knocked down endogenous IA-2 in NCI-H82 and NCI-
H345 cells with IA-2 siRNA. A significant reduction in 
cell proliferation was observed in both cell lines, with 
the greatest reduction occurring in the NCI-H82 cell 
line (60  %), compared to the NCI-H345 cell line (40  %) 
at 4 days post-transfection (Fig. 2a, b). Previous reports 
showed that ACh acts as an autocrine growth factor. To 
investigate whether IA-2 could regulate ACh content and 
secretion in SCLC cells, both were measured by ELISA 
after cells were transfected with IA-2 siRNA for 4 days. 
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As seen in Fig. 2c and e, both ACh cell content and ACh 
secretion were decreased by ~20 and ~30 %, respectively 
in NCI-H82 cells, as compared to the scramble siRNA 
control. Similar results were observed with NCI-H345 
cells (Fig. 2d, f ).
miR‑342 regulates IA‑2 expression in SCLC cells
To see if the expression of IA-2 is regulated by miRNAs, 
NCI-H82 and NCI-H345 cells were transfected with a 
miR-342 mimic or miR-342 inhibitor. As seen in Fig.  3, 
the miR-342 mimic significantly decreased the expres-
sion of IA-2 mRNA, whereas the miR-342 inhibitor 
significantly enhanced the expression of IA-2 mRNA in 
both cell lines (Fig. 3a, b). Western blot analysis showed 
that miR-342 mimic decreased, whereas miR-342 
inhibitor enhanced protein expression in both cell lines 
(Fig. 3c–f).
MiR‑342 mimic suppresses IA‑2 expression, SCLC cell 
growth and ACh content and secretion
Given that miR-342 directly targets IA-2 as previously 
demonstrated in the insulin-containing MIN6 cells by 
“RNA immunoprecipitation PCR with anti-argonaute 2” 
[25], the impact of miR-342 on SCLC cell proliferation 
Fig. 1 IA-2 expression is decreased by siRNA. a The knockdown of endogenous IA-2 mRNA by siRNA (determined by quantitative RT-PCR analysis), 
was reduced ~80 % in NCI-H82. b Western blot shows that protein levels for IA-2 (as evaluated by anti-IA-2 N-terminal #49 antibody), was also sig-
nificantly reduced. Three major bands of IA-2 are detected as indicated due to post-translational modifications [33]. c IA-2 protein level was reduced 
~70 % as determined by the intensity of the 90-kDa bands using the NIH Image J program. d Immunostaining with the IA-2 N-terminal antibody 
shows that the level of IA-2 in IA-2-specific RNAi treated NCI-H82 cells was significantly lower than the control cells. Data (mean ± SE) were derived 
from three independent experiments (in triplicate), and normalized to GAPDH mRNA levels. **P < 0.01
Page 5 of 10Xu et al. J Transl Med  (2016) 14:278 
was evaluated. Growth curve analysis showed that NCI-
H82 and NCI-H345 cells treated with the miR-342 mimic 
significantly suppressed SCLC cell proliferation by as 
much as 30 % (Fig. 4a, b). In contrast, the miR-342 inhibi-
tor produced a slight but significant increase in SCLC cell 
proliferation at 4 days after transfection (Fig. 4a, b).
To determine the effect of miR-342 on ACh cell con-
tent and secretion, SCLC cells were transfected with a 
miR-342 mimic or inhibitor. Both NCI-H82 and NCI-
H345 cells transfected with the miR-342 mimic showed 
a significant reduction in ACh cell content and secre-
tion (Fig. 4c–f). NCI-H82 cells treated with the miR-342 
inhibitor showed a slight but not significant increase 
in ACh secretion (Fig.  4e–f), and a barely significant 
increase in ACh content (Fig. 4c).
ACh rescues the inhibitory effects IA‑2 siRNA or miR‑342 
mimic on SCLC proliferation
To confirm that the effect of IA-2 siRNA and miR-342 
on SCLC cell proliferation is mediated through the ACh 
autocrine growth loop, ACh was added to the culture 
medium of the NCI-H82 cells that were treated with 
either the scrambled siRNA, IA-2 siRNA, miR-342 mimic, 
or the miR-342 inhibitor. As seen in Fig. 5a, the addition 
of ACh to control cells resulted in significantly increas-
ing the amount of cell proliferation by as much as 50 %. 
Fig. 2 IA-2 silencing by RNAi leads to reduced SCLC cell proliferation and ACh secretion. a, b Effects of IA-2 RNAi on cell growth in both NCI-H82 
and NCI-H345 cells. Cells were treated with IA-2 siRNA for 1–4 days (n = 4). Secreted ACh levels (e, f) and intracellular ACh levels (content) (c, d), 
were measured after four days of IA-2 siRNA (n = 3). Data (mean ± SE) were derived from three independent experiments performed in triplicate 
and normalized to total cell numbers. *P < 0.05, **P < 0.01
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An even greater increase in proliferation was observed 
when IA-2 siRNA treated cells were incubated with ACh 
(1 mM, optimal concentration). Similarly, ACh produced 
a highly significant increase in the proliferation of cells 
that had been treated with miR-342 mimic (Fig.  5b). 
Finally, the addition of ACh to cells that had been treated 
with the miR-342 inhibitor produced an increase in cell 
proliferation with the greatest magnitude compared to the 
other treatment conditions (Fig. 5b). Taken together, these 
findings show for the first time, that the neurotransmit-
ter ACh is effective in rescuing the inhibitory effects of 
siRNA and miR-342 on cell proliferation.
Fig. 3 miR-342 regulates IA-2 expression level in SCLC cells. a, b Effects of miR-342 mimic and miR-342 inhibitor on IA-2 expression in NCI-H82 and 
NCI-H345 cells (n = 4), as quantitated by Real-Time PCR. Relative mRNA levels were normalized to GAPDH. c, d Protein levels for IA-2 in NCI-H82 
and NCI-H345 cells (n = 4) were quantitated by Western blotting using the anti-IA-2 antibody. e, f Relative expression levels of IA-2 in Western blots 
(normalized by α-tubulin), were determined by NIH Image J. *p < 0.05; **p < 0.01
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Discussion
Our previous studies demonstrated that IA-2 is highly 
expressed in multiple human SCLC cell samples [18], but 
not in normal lung tissue. Although IA-2 has been well 
characterized in many neuroendocrine cells, its char-
acterization and function in SCLC have so far not been 
determined. In this study, we found that high expression 
of IA-2 is associated with the growth and proliferation of 
SCLC cells. Conversely, we also demonstrated that the 
knockdown of IA-2 expression by RNAi can significantly 
reduce the growth rate of SCLC cells.
SCLC cells have the capacity to synthesize and secrete 
ACh [6, 7] and a cholinergic autocrine loop positively 
regulates SCLC cell growth [6, 26]. On the cytoplasmic 
Fig. 4 Inhibitory effect of miR-342 mimic on SCLC growth and ACh secretion. a, b Cell growth rates (based on cell count), were significantly 
reduced in both NCI-H82 and NCI-H345 cell lines transfected with the miR-342 mimic. A barely significant increase in cell growth was observed in 
the cells treated with the miR-342 inhibitor (96 h after treatment; n = 6). ACh secretion levels (e, f), and intracellular ACh content (c, d), were meas-
ured in both NCI-H82 and NCI-H345 cells after transfecting with either the miR-342 mimic or the miR-342 inhibitor 4 days post-transfection. (n = 3). 
Data (mean ± SE) were derived from three independent experiments (in triplicate) and normalized to total cell numbers. *P < 0.05, **P < 0.01
Page 8 of 10Xu et al. J Transl Med  (2016) 14:278 
membrane, two types of ACH receptors have been found: 
nAChR ligand-gated ion channels (α3, α5, α7, β2 and 
β4) and G protein-coupled receptors mAChR (M3 and 
M5) [6, 27–30]. Moreover, the knockdown of choline 
transporter-like protein 4 (CTL4), which mediates ACh 
synthesis and secretion, has been shown to significantly 
depress the growth of SCLC (NCI-H82) cells without 
affect choline uptake [31].
In the present study, we showed that silencing of IA-2 
results in a substantial decrease in SCLC cell growth sec-
ondary to a decrease in the content and secretion of ACh 
(Fig. 6). The silencing of IA-2 has previously been shown 
to decrease the stability and number of DCV and, in 
turn, the secretion of hormones and neurotransmitters. 
In the present study, we also showed that overexpression 
of the miR-342, which targets the 3′-UTR (untranslated 
Fig. 5 ACh rescues the inhibitory effect of IA-2 siRNA and miR-342 mimic on SCLC cell growth. a Treatment of SCLC cells with IA-2 siRNA inhibits 
cell growth. In contrast, treatment of NCI-H82 cells with ACh (1 mM), rescues cell growth. The increase of proliferation in the IA-2 siRNA and ACh 
treated cells is significantly higher than that incubated with ACh. b Similarly, the inhibitory effect of miR-342 on NCI-H82 cell growth is reduced by 
ACh treatment (1 mM). Similarly, the addition of ACh to cells treated with the miR-342 inhibitor produced an increase in cell proliferation with the 
greatest magnitude compared to the other treatment conditions. n = 4; *P < 0.05, **P < 0.01
Fig. 6 Schematic representation of the effects of IA-2 siRNA and miR-342 mimic on SCLC cell proliferation through ACh autocrine function
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region) of IA-2, results in a decrease in the expression 
of IA-2 mRNA and, in turn, a decrease in the cellular 
content and secretion of ACh resulting in a decrease in 
the growth of SCLC cells (Fig.  6). Further support for 
the idea that the decrease in ACh is responsible for the 
decrease in SCLC cell growth was obtained by restor-
ing cell growth to nearly normal levels by treatment with 
ACh.
SCLC is an aggressive malignancy with a distinct nat-
ural history and poor prognosis, leading to the death of 
approximately 16,000 patients per year in United States. 
For decades, cytotoxic chemotherapy has remained the 
backbone of treatment since SCLC is a chemo-sensitive 
tumor. Nonetheless, high response rates are not usually 
translated into cure. In spite of recent advances in eluci-
dating aberrant molecular pathways and new therapeutic 
targets, no significant improvement in patients’ survival 
has been demonstrated [32].
Conclusion
Taken together, the demonstration that both miR-342 
and its target gene IA-2 are involved in the growth of 
SCLC cells, through their effect on the secretion of 
acetylcholine, represents a novel approach that may 
be therapeutically useful in the treatment of SCLC 
tumors.
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